What the studies show
Small trials report modest short-term improvements on cognitive scales; no large or long trial, no regulatory approval in a major market for this use.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Cerebrolysin randomised trials in Alzheimer's disease and traumatic brain injury.PubMed searchSmall trials, largely from countries where the product is established.
In context
Cerebrolysin is a mixture of short peptides and amino acids extracted from pig brain, made in Austria and given as a course of daily intravenous infusions for stroke, dementia and brain injury in Russia, China, Eastern Europe and Asia. It is not approved in the United States, the United Kingdom or EU-wide. The Cochrane review of seven stroke trials found no effect on death and a doubling of non-fatal serious adverse events; the Cochrane review of six vascular-dementia trials found a small cognitive benefit on very low-quality evidence that may be too small to matter.
Cerebrolysin is approved in austria, russia, china and others; not us/uk/eu-wide. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Cerebrolysin proven to help with alzheimer's disease?
What studies are behind the grade?
Is Cerebrolysin approved for this?
Other outcomes for Cerebrolysin
- ASurvival after acute ischaemic strokeCochrane review: 6 RCTs, 1,689 participants
- CCognition in vascular dementiaCochrane review: 6 RCTs, 597 participants
- CTraumatic brain injury recoverySmall RCTs and cohort studies
- ASerious adverse events (stroke)adverseCochrane review: 3 RCTs, 1,335 participants
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →